Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A5 Laboratories, a contract research based organisation servicing the pharmaceutical and biotechnology companies in North America, said its European partner has begun preparation and production of the VI-1718 interferon product.
Subscribe to our email newsletter
Using A5 Labs production technology, it is anticipated that approximately 2,000 doses of the VI-1718 will be manufactured with certificates of analysis in the next 4 weeks.
A5 Labs expects that it will begin a multi-center production and in-vitro test of the interferon product to establish proof of concept potency in the next 6 to 8 weeks.
A5 Labs president and CEO Richard Azani said in the next 6 to 8 weeks they plan further production and testing the product for its potency and efficacy in independent labs, the results of which will be a significant milestone towards initiation of submission for animal and human clinical trials.